ADA Obesity Guideline 2026 Restructures Drug Selection by Comorbidity

The ADA obesity guideline 2026 ties drug class to specific complications such as HFpEF, MASH, OSA, and osteoarthritis. The shift gives family physicians a clearer framework for matching agent to patient.

April 26, 2026 · 3 min read

The Story at a Glance:

The new ADA obesity guideline (January 13, 2026) recommends drugs by coexisting condition rather than by BMI alone.
GLP-1 receptor agonists (GLP-1 RAs) and dual GIP/GLP-1 RAs are preferred for patients with type 2 diabetes, ASCVD, HFpEF, MASH, OSA, or osteoarthritis.
The 23-page chapter contains 34 evidence-based recommendations and reflects evidence through 2025.
Lifestyle therapy and shared decision-making remain required components of every pharmacologic plan.

What Happened

The new ADA obesity guideline was published on January 13, 2026, by the Obesity Association, a division of the American Diabetes Association. The 23-page chapter, titled Pharmacologic Treatment of Obesity in Adults, appears in the inaugural issue of the ADA’s new journal Diabetes, Obesity, and Cardiometabolic Care.

The chapter contains 34 evidence-based recommendations organized around seven topics, including how to discuss obesity medications with patients, set treatment goals, select an agent, and manage long-term care.

The document replaces a primarily BMI-driven approach with one that ties drug selection to coexisting conditions: type 2 diabetes (T2D), atherosclerotic cardiovascular disease (ASCVD), heart failure with preserved ejection fraction (HFpEF), metabolic dysfunction–associated steatohepatitis (MASH), obstructive sleep apnea (OSA), and osteoarthritis (OA).

Why the ADA Obesity Guideline Matters for Primary Care

For family physicians, the new guidance closes a long-standing gap between obesity care and cardiometabolic disease management. Most patients seen in primary care carry two or more obesity-related complications, and the previous lack of comorbidity-specific guidance left clinicians weighing efficacy data without a clear framework.

The 2026 chapter sorts FDA-approved agents — including liraglutide, semaglutide, tirzepatide, naltrexone–bupropion, phentermine–topiramate, and orlistat — by the strength of evidence (A-level versus B/C-level) for each obesity-related condition. That structure lets primary care match a drug to the most clinically consequential coexisting disease, not the highest BMI alone.

ADA Obesity Guideline: Drug Class by Comorbidity

The guideline reorganizes pharmacologic options into recommendations specific to each major obesity-related complication. Highlights for family physicians include:

T2D + obesity: A GLP-1 RA or dual GIP/GLP-1 RA is preferred for combined weight reduction and glucose-lowering efficacy.
ASCVD + obesity: Use a GLP-1 RA with demonstrated cardiovascular benefit (semaglutide, based on the SELECT trial) or a dual GIP/GLP-1 RA with potential benefit.
HFpEF + obesity: Choose agents with demonstrated improvement in heart-failure symptoms — semaglutide (STEP-HFpEF program) or tirzepatide (SUMMIT trial).
MASH with moderate-to-advanced fibrosis: A GLP-1 RA or dual GIP/GLP-1 RA is recommended for demonstrated or potential MASH benefit.
Moderate-to-severe OSA: Prioritize an agent with demonstrated improvement in apnea-hypopnea index (AHI), such as tirzepatide (SURMOUNT-OSA).
Moderate osteoarthritis: Prioritize a GLP-1 RA or dual GIP/GLP-1 RA with potential improvement in pain and physical function.

Placebo-subtracted weight loss across meta-analyses cited in the chapter ranges from roughly 3% with orlistat to about 18% with tirzepatide at maximum tolerated dose, against an average 2.6% weight reduction with lifestyle counseling alone.

What Experts Are Saying

Samar Hafida, MD, vice president of the Obesity Association and an endocrinologist at the Joslin Diabetes Center in Boston, told Medscape Medical News that the chapter offers detailed guidance on specific medication classes to select based on proven health benefit.

“Detailed guidance on specific medication classes to select.” — Samar Hafida, MD, Joslin Diabetes Center; Vice President, Obesity Association

Jonathan Q. Purnell, MD, president of The Obesity Society and an independent commentator, said the new standards help position obesity medications as standard cardiometabolic therapy alongside the upcoming joint US guideline from The Obesity Society, the Obesity Medicine Association, and the Obesity Action Coalition.

What’s Next

Coverage and access remain the critical near-term variables. The chapter urges clinical practices to allocate staff time for prior-authorization work so insurance requirements do not dictate drug choice. A separate joint US document from The Obesity Society, the Obesity Medicine Association, and the Obesity Action Coalition was scheduled for release in late January 2026, and a tirzepatide cardiovascular outcomes trial is ongoing. Family physicians should expect continued updates as evidence on dual GIP/GLP-1 agonists in HFpEF, OSA, and OA matures.

Bottom Line

Match the ADA obesity guideline drug class to each patient’s most consequential complication, not BMI alone.
Initiate dose escalation gradually and continue therapy after goals are reached, since discontinuation predicts weight regain.
Pair every prescription with structured lifestyle therapy, in-house or via referral to a registered dietitian or behavioral program.
Document a shared decision-making conversation that covers contraindications, adverse-effect profile, and out-of-pocket cost.

Sources

The Obesity Association (ADA). Pharmacologic Treatment of Obesity in Adults: Standards of Care in Overweight and Obesity. Diabetes, Obesity, and Cardiometabolic Care, January 13, 2026. Pharmacologic Treatment of Obesity in Adults — full text
American Diabetes Association Professional Practice Committee. 8. Obesity and Weight Management for the Prevention and Treatment of Diabetes: Standards of Care in Diabetes—2026. Diabetes Care, January 1, 2026. Standards of Care in Diabetes—2026, Section 8
Tucker M. New Standards Address Pharmacologic Obesity Treatment. Medscape Medical News, January 14, 2026. Medscape coverage of the ADA Obesity Association standards
American Diabetes Association. The Obesity Association Publishes New Standards of Care Section on Obesity Medications. ADA Press Release, January 13, 2026. ADA press release announcing the new standards
Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity (STEP-HFpEF). NEJM, August 25, 2023. STEP-HFpEF primary results in NEJM
Packer M, Zile MR, Kramer CM, et al. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity (SUMMIT). NEJM, January 30, 2025. SUMMIT trial primary results in NEJM